Botanix Pharmaceuticals has announced the promotion of Paul Seaback to Chief Operating Officer, a move the commercial dermatology company said will strengthen day-to-day operations and drive strategic growth across its Philadelphia and Phoenix businesses.

Entropy Neurodynamics has reported Phase 2a results suggesting a potential new direction for patients with treatment-resistant irritable bowel syndrome.

Telix Pharmaceuticals is positioning a new generation of PSMA-targeted therapies to overcome limitations seen when first-generation radioligand therapies are moved into earlier lines of prostate cancer care.

Syntara CEO Gary Phillips said, “We’re very grateful for the strong support from our shareholders and new investors in this capital raising, stemming from the positive FDA review of our clinical development plan and Phase 2b protocol for amsulostat."

Mesoblast has reached a key milestone in its bid to bring a non-opioid, disease-modifying treatment for chronic low back pain to market, announcing that the pivotal Phase 3 trial of rexlemestrocel L has hit its patient recruitment target.

AVITA Medical has secured regulatory clearance in Australia and a WAND listing in New Zealand for RECELL GO, its next-generation system for preparing RECELL Spray On Skin.

Emyria has reached an agreement with Matilda Healthcare to open an Empax clinic at Matilda Nepean Private Hospital in Kingswood, expanding the company's presence in New South Wales and increasing its national footprint.

A new analysis released during World Immunisation Week 2026 has sharpened the focus on a persistent weakness in Australia’s health system, highlighting a gap between strong early-stage vaccine research and its translation into real-world outcomes.

Under the agreement, CLEO will build on its existing work using Bio-Techne’s Ella platform, which the company has been using in-house and which has demonstrated the ability to deliver CLEO’s biomarker panel with high sensitivity, precision, and reproducibility.

The company said VP-001 has the potential to become the first approved treatment for patients with RP11, a genetic eye disease with no available therapies.

Algorae said the collaboration establishes a framework for joint prioritisation of products based on regulatory pathways, supply readiness and market access considerations.

Managing director Paul Rennie said the level of investor support underscored confidence in the company’s Phase 3 program and its upcoming interim analysis.

ImmVirX has used one of the world’s largest cancer research stages to sharpen its pitch that oncolytic RNA immunotherapies could materially shift outcomes in some of the most difficult-to-treat tumours.

The company has been examining in greater detail how often the treatment may need to be administered, with a focus on identifying an optimal dosing regimen as it prepares the next stage of clinical development and regulatory engagement.

Amplia Therapeutics has used one of the world’s largest oncology stages to sharpen its case for narmafotinib, presenting mature data from its ACCENT trial that suggest the drug could meaningfully shift outcomes in one of the most difficult-to-treat cancers.

The Melbourne-based biotechnology company confirmed that a recent Type C meeting with the regulator received positive feedback on both the proposed phase 1 trial design and the broader clinical strategy for DEP HER2, a dendrimer-based radioligand therapy for difficult-to-treat cancers.

The trial, known as R327 G301, is progressing across five sites in Indonesia, with patient dosing ongoing and an interim analysis planned once 155 patients have been completed.